Spyre Therapeutics recently completed a US$403.0 million follow-on equity offering at US$62 per share after reporting positive 12-week Phase 2 SKYLINE data for its ulcerative colitis candidate SPY001.

In the event of a ceasefire, the JPMorgan trading desk sees technology, consumer and financial stocks rallying.

Investors head into what could be the most consequential week of the Iran conflict, scrambling to position for binary ...

That human-accountable model makes the most sense to me. By all means, integrate AI into the systems employees already use ...

Get ahead of the game with our best 2026 Emmy Award prediction market picks. Analyze 'Yes' and 'No' prices for frontrunners ...

Amid injuries, nonstop drama and consistently poor play, the Bucks drifted aimlessly toward the lottery. On Sunday, their ...

Betfair Predicts is being trialed among select U.K. users, offering a revamped exchange-style platform for peer-to-peer ...

President Donald Trump’s latest deadline for Iran to agree to a deal is just hours away, and investors are once again finding ...

Pokémon is currently thriving in the Nintendo Switch with games like Legends: Arceus and Scarlet and Violet, but which of the ...

This Polymarket platform has created such a momentum among the budding startups and entrepreneurs to create a platform ...

In an interview with Mint, Rishabh Nahar of Qode Advisors discusses the current market structure. With a unique 'all-weather' ...